Benjamin W Teh1,2, Simon J Harrison2,3, Monica A Slavin1,4,5, Leon J Worth1,4. 1. Department of Infectious Diseases, Peter MacCallum Cancer Centre, Parkville, Victoria, Australia. 2. Sir Peter MacCallum Department of Oncology, Peter MacCallum Cancer Centre, Parkville, Victoria, Australia. 3. Department of Haematology, Peter MacCallum Cancer Centre, Parkville, Victoria, Australia. 4. Department of Medicine, University of Melbourne, Parkville, Victoria, Australia. 5. Victorian Infectious Diseases Service, Doherty Institute for Infection and Immunity, Parkville, Victoria, Australia.
Abstract
BACKGROUND: Bloodstream infections (BSIs) are a significant complication of treatment for multiple myeloma (MM). The objective of this study was to define the epidemiology of BSI with current era MM treatment regimens, including immunomodulatory drugs, proteasome inhibitors and autologous haematopoietic stem cell transplantation (ASCT). METHODS: Clinical and microbiology records of patients with MM diagnosed between 2008 and 2012 were reviewed using a standardised tool to capture patient demographics, myeloma characteristics and BSI characteristics (type, severity, outcomes). Conditional risk set modelling was used to determine clinical predictors of BSI. RESULTS: Of 199 studied patients, 71 (35.6%) had confirmed BSI (98 infection episodes). Peak incidence was 65.1 infections/100 patient-years at 4-6 months following MM diagnosis with a late peak at 64-66 months. Gram-positive pathogens were responsible for the majority (54.5%) of infections during induction, whilst gram-negative pathogens were responsible for the majority (57.7%) of infections during disease progression. Overall, Escherichia coli was the most frequently identified pathogen. Streptococcus pneumoniae comprised 6.1% of all BSIs at a median of 7.5 months following MM diagnosis. Highest rates of ICU admission (23.1%) and mortality (11.5%) were seen with BSIs in patients with progressive disease. Recent ASCT was independently associated with increased BSI risk (HR 3.09, P = 0.05). CONCLUSIONS: Treatment of progressive disease is a high-risk period for infection, evidenced by high proportions of BSI due to gram-negative pathogens and S. pneumoniae. Targeted evaluation of preventative strategies (prophylaxis, vaccination) to reduce morbidity and mortality during this period is required.
BACKGROUND: Bloodstream infections (BSIs) are a significant complication of treatment for multiple myeloma (MM). The objective of this study was to define the epidemiology of BSI with current era MM treatment regimens, including immunomodulatory drugs, proteasome inhibitors and autologous haematopoietic stem cell transplantation (ASCT). METHODS: Clinical and microbiology records of patients with MM diagnosed between 2008 and 2012 were reviewed using a standardised tool to capture patient demographics, myeloma characteristics and BSI characteristics (type, severity, outcomes). Conditional risk set modelling was used to determine clinical predictors of BSI. RESULTS: Of 199 studied patients, 71 (35.6%) had confirmed BSI (98 infection episodes). Peak incidence was 65.1 infections/100 patient-years at 4-6 months following MM diagnosis with a late peak at 64-66 months. Gram-positive pathogens were responsible for the majority (54.5%) of infections during induction, whilst gram-negative pathogens were responsible for the majority (57.7%) of infections during disease progression. Overall, Escherichia coli was the most frequently identified pathogen. Streptococcus pneumoniae comprised 6.1% of all BSIs at a median of 7.5 months following MM diagnosis. Highest rates of ICU admission (23.1%) and mortality (11.5%) were seen with BSIs in patients with progressive disease. Recent ASCT was independently associated with increased BSI risk (HR 3.09, P = 0.05). CONCLUSIONS: Treatment of progressive disease is a high-risk period for infection, evidenced by high proportions of BSI due to gram-negative pathogens and S. pneumoniae. Targeted evaluation of preventative strategies (prophylaxis, vaccination) to reduce morbidity and mortality during this period is required.
Authors: Michael A Thompson; Martin K Oaks; Maharaj Singh; Karen M Michel; Michael P Mullane; Husam S Tarawneh; Angi Kraut; Kayla J Hamm Journal: J Patient Cent Res Rev Date: 2017-08-10
Authors: Anna Waszczuk-Gajda; Olaf Penack; Giulia Sbianchi; Linda Koster; Didier Blaise; Péter Reményi; Nigel Russell; Per Ljungman; Marek Trneny; Jiri Mayer; Simona Iacobelli; Guido Kobbe; Christof Scheid; Jane Apperley; Cyrille Touzeau; Stig Lenhoff; Esa Jantunen; Achilles Anagnostopoulos; Laura Paris; Paul Browne; Catherine Thieblemont; Nicolaas Schaap; Jorge Sierra; Ibrahim Yakoub-Agha; Laurent Garderet; Jan Styczynski; Helene Schoemans; Ivan Moiseev; Rafael F Duarte; Zinaida Peric; Silvia Montoto; Anja van Biezen; Malgorzata Mikulska; Mahmoud Aljurf; Tapani Ruutu; Nicolaus Kröger; Curly Morris; Christian Koenecke; Stefan Schoenland; Grzegorz W Basak Journal: J Clin Med Date: 2022-06-20 Impact factor: 4.964
Authors: Andinet Alemu; Maharaj Singh; Chris Blumberg; John O Richards; Martin K Oaks; Michael A Thompson Journal: J Patient Cent Res Rev Date: 2017-04-25
Authors: Cristina Encinas; José-Ángel Hernandez-Rivas; Albert Oriol; Laura Rosiñol; María-Jesús Blanchard; José-María Bellón; Ramón García-Sanz; Javier de la Rubia; Ana López de la Guía; Ana Jímenez-Ubieto; Isidro Jarque; Belén Iñigo; Victoria Dourdil; Felipe de Arriba; Clara Cuéllar Pérez-Ávila; Yolanda Gonzalez; Miguel-Teodoro Hernández; Joan Bargay; Miguel Granell; Paula Rodríguez-Otero; Maialen Silvent; Carmen Cabrera; Rafael Rios; Adrián Alegre; Mercedes Gironella; Marta-Sonia Gonzalez; Anna Sureda; Antonia Sampol; Enrique M Ocio; Isabel Krsnik; Antonio García; Aránzazu García-Mateo; Joan-Alfons Soler; Jesús Martín; José-María Arguiñano; María-Victoria Mateos; Joan Bladé; Jesús F San-Miguel; Juan-José Lahuerta; Joaquín Martínez-López Journal: Blood Cancer J Date: 2022-04-19 Impact factor: 9.812
Authors: Marcel Doerflinger; Alexandra L Garnham; Saskia Freytag; Simon J Harrison; H Miles Prince; Hang Quach; Monica A Slavin; Marc Pellegrini; Benjamin W Teh Journal: Clin Transl Immunology Date: 2021-01-07